Skip to main content

Table 4 Cumulative incidence of revision at 1 and 5 years’ follow-up and effect of comorbidities from the Elixhauser index on the risk of revision in Total Hip Arthroplasty (THA)

From: Impact of comorbidity on the short- and medium-term risk of revision in total hip and knee arthroplasty

  1 year follow-up 5 years’ follow-up
Np Nr Incidence (95% CI) SHR (95%CI) p value Np Nr incidence (95% CI) SHR (95% CI) P value
Burden of comorbidity      0.021      0.030
 0 comorbidities 6270 61 0.92 (0.71–1.18) 1.00   3391 79 2.45 (2.06–2.88) 1.00  
 1 comorbidity 5501 70 1.17 (0.92–1.47) 1.29 (0.91–1.84)   2717 56 2.33 (1.95–2.77) 1.09 (0.85–1.40)  
 > =2 comorbidities 4388 68 1.39 (1.10–1.76) 1.51 (1.05–2.15)   1927 53 2.94 (2.44–3.50) 1.32 (1.03–1.71)  
Uncomplicated hypertension 7161 100 1.29 (1.06–1.56) 1.21 (0.91–1.62) 0.189 3448 78 2.60 (2.23–3.00) 1.12 (0.91–1.38) 0.276
Uncomplicated diabetes 1949 31 1.43 (0.99–2.00) 1.30 (0.89–1.92) 0.177 901 24 2.91 (2.21–3.76) 1.25 (0.94–1.67) 0.130
Obesity 1072 23 1.90 (1.24–2.79) 1.81 (1.17–2.80) 0.007 479 21 4.39 (3.21–5.84) 1.80 (1.31–2.47) < 0.001
Depression 1030 15 1.32 (0.77–2.12) 1.16 (0.69–1.97) 0.575 455 16 3.35 (2.30–4.72) 1.28 (0.89–1.85) 0.185
Chronic pulmonary disease 1270 20 1.42 (0.90–2.16) 1.32 (0.83–2.07) 0.240 564 11 2.52 (1.74–3.54) 1.07 (0.74–1.54) 0.729
Hypothyroidism 668 8 1.08 (0.51–2.05) 0.92 (0.45–1.90) 0.825 262 6 2.44 (1.36–4.05) 0.87 (0.51–1.50) 0.625
Deficiency anemia 421 6 1.28 (0.54–2.65) 1.14 (0.51–2.53) 0.752 187 6 2.91 (1.58–4.90) 1.26 (0.71–2.23) 0.421
Renal failure 323 4 1.04 (0.35–2.51) 0.85 (0.31–2.33) 0.753 100 2 1.84 (0.75–3.84) 0.84 (0.39–1.89) 0.667
Hypertension with complications 254 1 0.33 (0.03–1.72) 0.27 (0.04–1.94) 0.192 69 1 0.75 (1.50–2.51) 0.36 (0.09–1.45) 0.151
Valvular disease 259 2 0.69 (0.14–2.31) 0.55 (0.14–2.20) 0.399 113 0 NR NC NC
Rheumatoid arthritis 249 3 1.06 (0.30–2.87) 0.93 (0.30–2.90) 0.898 101 4 2.88 (1.27–5.62) 1.16 (0.55–2.45) 0.690
Other neurological disorders 212 3 1.29 (0.36–3.49) 1.17 (0.38–3.67) 0.780 88 2 2.23 (0.84–4.85) 1.07 (0.44–2.59) 0.882
Liver disease 245 2 0.71 (0.14–2.38) 0.71 (0.18–2.87) 0. 630 106 5 3.42 (1.68–6.69) 1.23 (0.59–2.59) 0.581
Congestive heart failure 131 2 1.36 (0.27–4.42) 1.10 (0.27–4.51) 0. 895 52 0 NR NC NC
Peripheral vascular disorders 143 3 1.85 (0.51–4.93) 1.73 (0.54–5.40) 0. 349 67 4 5.39 (2.31–10.38) 2.24 (1.06–4.74) 0.034
Solid tumor 87 1 1.08 (0.09–5.25) 0.87 (0.12–6.13) 0. 885 40 1 2.20 (0.42–6.97) 1.01 (0.25–4.06) 0.987
Diabetes with complications 55 0 NR NC NC 22 0 NR NC NC
Coagulopathy 71 0 NR NC NC 37 0 NR NC NC
Blood loss anemia 65 0 NR NC NC 39 0 NR NC NC
Fluid and electrolyte disorders 113 1 0.80 (0.07–3.99) 0.68 (0.10–4.81) 0.701 47 1 1.67 (0.32–5.36) 0.77 (0.19–3.10) 0.715
Alcohol abuse 110 2 1.69 (0.33–5.42) 1.81 (0.47–7.23) 0.404 48 0 NR NC NC
Psychoses 65 2 2.72 (0.52–8.49) 2.62 (0.65–10.63) 0.176 17 2 5.88 (1.89–13.23) 2.77 (1.03–7.49) 0.044
Paralysis 35 1 2.63 (0.20–11.79) 2.46 (0.36–16.87) 0.375 14 1 5.58 (1.00–16.41) 2.55 (0.63–10.28) 0.188
Pulmonary circulation disorders 17 0 NR NC NC 9 0 NR NC NC
Lymphoma 16 1 6.25 (0.41–24.69) 5.32 (0.75–37.33) 0.092 4 0 NR NC NC
Peptic ulcer disease 3 0 NR NC NC 3 0 NR NC NC
Drug abuse 23 0 NR NC NC 10 0 NR NC NC
Metastatic cancer 5 1 10.0 (0.57–35.81) 12.23 (1.46–102.46) 0.021 3 0 NR NC NC
Weight loss 6 0 NR NC NC 2 0 NR NC NC
AIDS 14 1 7,14 (0.45–27.52) 8.17 (0.82–56.81) 0.089 6 0 NR NC NC
  1. np number of primary procedures at 1 and 5 years’ follow-up, nr number of revision procedures since the primary operation (from the beginning to 1 year and from 1 year to 5 years, at follow-up), SHR Subhazard ratio from competing risks models adjusted for sex, age, year of intervention, fixation type and type of hospital, NR no revisions undergone from 1 to 5 years’ follow-up, NC Not calculable
  2. Incidence (95%CI): cumulative incidence of revision considering patient death as a competing event and the 95% Confidence Interval
  3. Variance inflation tests < 4 for all models